UB Paderborn / Katalog / Suche / in CDI

Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...

1 – 25 von 8.767

Sortiert nach

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer

European journal of cancer (1990), 2016-01, Vol.52, p.1-9

2016

Volltextzugriff (PDF)

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial

Annals of oncology, 2019-02, Vol.30 (2), p.281-289

2019

Volltextzugriff (PDF)

HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients

Annals of oncology, 2020-07, Vol.31 (7), p.902-911

2020

Volltextzugriff (PDF)

Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial

Annals of oncology, 2017-02, Vol.28 (2), p.292-297

2017

Volltextzugriff (PDF)

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer

Annals of oncology, 2022-02, Vol.33 (2), p.169-180

2022

Volltextzugriff (PDF)

A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy

Annals of oncology, 2020-10, Vol.31 (10), p.1397-1404

2020

Volltextzugriff (PDF)

CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials

Annals of oncology, 2018-03, Vol.29 (3), p.687-693

2018

Volltextzugriff (PDF)

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

The New England journal of medicine, 2017-02, Vol.376 (7), p.629-640

2017

Volltextzugriff (PDF)

Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer

Annals of oncology, 2013-08, Vol.24 (8), p.2088-2092

2013

Volltextzugriff (PDF)

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer

Annals of oncology, 2020-04, Vol.31 (4), p.507-516

2020

Volltextzugriff (PDF)

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study

Annals of oncology, 2023-03, Vol.34 (3), p.262-274

2023

Volltextzugriff (PDF)

Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?

Annals of oncology, 2020-11, Vol.31 (11), p.1582-1582

2020

Volltextzugriff (PDF)

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Annals of oncology, 2015-05, Vol.26 (5), p.894-901

2015

Volltextzugriff (PDF)

Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing

Annals of oncology, 2015-01, Vol.26 (1), p.161-166

2015

Volltextzugriff (PDF)

Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Annals of oncology, 2020-11, Vol.31 (11), p.1536-1544

2020

Volltextzugriff (PDF)

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Annals of oncology, 2017-04, Vol.28 (4), p.874-881

2017

Volltextzugriff (PDF)

136O Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial

Journal of thoracic oncology, 2016-04, Vol.11 (4), p.S115-S115

2016

Volltextzugriff (PDF)

Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial

Annals of oncology, 2023-03, Vol.34 (3), p.251-261

2023

Volltextzugriff (PDF)

Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma

Annals of oncology, 2017-06, Vol.28 (6), p.1250-1259

2017

Volltextzugriff (PDF)

Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer

Annals of oncology, 2021-03, Vol.32 (3), p.395-403

2021

Volltextzugriff (PDF)

A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer

Annals of oncology, 2015-04, Vol.26 (4), p.762-768

2015

Volltextzugriff (PDF)

Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

Annals of oncology, 2019-11, Vol.30 (11), p.1831-1839

2019

Volltextzugriff (PDF)

Detection of bovine coronavirus in nasal swab of non‐captive wild water deer, Korea

Transboundary and emerging diseases, 2018-06, Vol.65 (3), p.627-631

2018

Volltextzugriff (PDF)

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence

Oral oncology, 2023-12, Vol.147, p.106587-106587, Article 106587

2023

Volltextzugriff (PDF)

Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study

ESMO open, 2023-12, Vol.8 (6), p.102068-102068, Article 102068

2023

Volltextzugriff (PDF)

1 – 25 von 8.767

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(7.671)
Mit Volltextzugriff
(7.892)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(8.590)
Japanisch
(1.187)
Koreanisch
(56)
Französisch
(46)
Russisch
(28)
Deutsch
(13)
Norwegisch
(10)
Spanisch
(4)
Persisch
(1)
Polnisch
(1)
Portugiesisch
(1)
Welsh
(1)

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

n.n

Thema

Science & Technology
(5.427)
Life Sciences & Biomedicine
(3.460)
Humans
(2.491)
Female
(1.566)
Male
(1.516)
Biological And Medical Sciences
(1.395)
Physical Sciences
(1.388)
Technology
(1.254)
Middle Aged
(1.073)
Physics
(1.070)
Medical Sciences
(1.057)
Adult
(1.017)
Animals
(955)
Aged
(715)
Exact Sciences And Technology
(589)
Engineering
(563)
Oncology
(480)
Materials Science
(457)
Fundamental And Applied Biological Sciences. Psychology
(440)
Biochemistry & Molecular Biology
(415)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(3.758)
Ingenta
(3.474)
MEDLINE
(3.386)
RCN full-text journals@Ovid
(2.603)
ScienceDirect
(2.010)
NUS Single-Journal Subscriptions
(1.972)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(1.404)
IngentaConnect Journals
(1.230)
Wiley-Blackwell Journals
(1.008)
Wiley Online Library
(724)
Springer journals
(618)
APS_美国物理学会期刊
(551)
IEEE Xplore
(492)
PROLA - Physical Review
(439)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(358)
Oxford Journals
(334)
Nature_系列刊
(251)
Oxford Journals 2020 Medicine
(227)
AIP Journals (American Institute of Physics)
(205)
Access via Taylor & Francis
(195)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(21)